The global AntCD20 monoclonal antibodies market is expected to grow at a CAGR of 8.5% during the forecast period, from 2021 to 2030. The growth of this market is driven by the increasing prevalence of cancer and neurological disorders, which are major drivers for the demand for AntCD20 monoclonal antibodies.
The first generation AntCD20 monoclonal antibody segment accounted for the largest share in 2018 and is expected to continue its dominance throughout the forecast period. The second generation AntCD20 monoclonal antibody segment is projected to grow at a CAGR of 9% during the forecast period, owing to its increased efficacy over first-generation products in terms of safety and efficacy profiles.
-The global Anti-CD20 Monoclonal Antibodies market is expected to grow at a CAGR of around 8.5% during the forecast period.
-The global Anti-CD20 Monoclonal Antibodies market is expected to reach USD 3,890 million by 2024 from USD 2,700 million in 2019.
-Increasing prevalence of chronic lymphocytic leukemia and other hematological disorders are driving the growth of the global Anti-CD20 Monoclonal Antibodies market.
Industry Growth Insights published a new data on “Anti-CD20 Monoclonal Antibodies Market”. The research report is titled “Anti-CD20 Monoclonal Antibodies Market research by Types (First Generation Anti-CD20 Monoclonal Antibody, Second Generation Anti-CD20 Monoclonal Antibody, Third Generation Anti-CD20 Monoclonal Antibody), By Applications (Oncology, Neurology, Immunology), By Players/Companies Genmab, Amgen, Celltrion, Roche, Novartis AG, Pfizer, Biogen, Genentech, Immunomedics, Spectrum Pharmaceuticals, Bio-Rad Laboratories, LFB Biotechnologie”.
Scope Of The Report
Report Attributes
Report Details
Report Title
Anti-CD20 Monoclonal Antibodies Market Research Report
By Type
First Generation Anti-CD20 Monoclonal Antibody, Second Generation Anti-CD20 Monoclonal Antibody, Third Generation Anti-CD20 Monoclonal Antibody
By Application
Oncology, Neurology, Immunology
By Companies
Genmab, Amgen, Celltrion, Roche, Novartis AG, Pfizer, Biogen, Genentech, Immunomedics, Spectrum Pharmaceuticals, Bio-Rad Laboratories, LFB Biotechnologie
Regions Covered
North America, Europe, APAC, Latin America, MEA
Base Year
2021
Historical Year
2019 to 2020 (Data from 2010 can be provided as per availability)
Forecast Year
2030
Number of Pages
250
Number of Tables & Figures
175
Customization Available
Yes, the report can be customized as per your need.
Global Anti-CD20 Monoclonal Antibodies Market Report Segments:
The global Anti-CD20 Monoclonal Antibodies market is segmented on the basis of:
Types
First Generation Anti-CD20 Monoclonal Antibody, Second Generation Anti-CD20 Monoclonal Antibody, Third Generation Anti-CD20 Monoclonal Antibody
The product segment provides information about the market share of each product and the respective CAGR during the forecast period. It lays out information about the product pricing parameters, trends, and profits that provides in-depth insights of the market. Furthermore, it discusses latest product developments & innovation in the market.
Applications
Oncology, Neurology, Immunology
The application segment fragments various applications of the product and provides information on the market share and growth rate of each application segment. It discusses the potential future applications of the products and driving and restraining factors of each application segment.
Some of the companies that are profiled in this report are:
- Genmab
- Amgen
- Celltrion
- Roche
- Novartis AG
- Pfizer
- Biogen
- Genentech
- Immunomedics
- Spectrum Pharmaceuticals
- Bio-Rad Laboratories
- LFB Biotechnologie
Highlights of The Anti-CD20 Monoclonal Antibodies Market Report:
- The market structure and projections for the coming years.
- Drivers, restraints, opportunities, and current trends of market.
- Historical data and forecast.
- Estimations for the forecast period 2030.
- Developments and trends in the market.
- By Type:
- First Generation Anti-CD20 Monoclonal Antibody
- Second Generation Anti-CD20 Monoclonal Antibody
- Third Generation Anti-CD20 Monoclonal Antibody
- By Application:
- Oncology
- Neurology
- Immunology
- Market scenario by region, sub-region, and country.
- Market share of the market players, company profiles, product specifications, SWOT analysis, and competitive landscape.
- Analysis regarding upstream raw materials, downstream demand, and current market dynamics.
- Government Policies, Macro & Micro economic factors are also included in the report.
We have studied the Anti-CD20 Monoclonal Antibodies Market in 360 degrees via. both primary & secondary research methodologies. This helped us in building an understanding of the current market dynamics, supply-demand gap, pricing trends, product preferences, consumer patterns & so on. The findings were further validated through primary research with industry experts & opinion leaders across countries. The data is further compiled & validated through various market estimation & data validation methodologies. Further, we also have our in-house data forecasting model to predict market growth up to 2030.
Regional Analysis
- North America
- Europe
- Asia Pacific
- Middle East & Africa
- Latin America
Note: A country of choice can be added in the report at no extra cost. If more than one country needs to be added, the research quote will vary accordingly.
The geographical analysis part of the report provides information about the product sales in terms of volume and revenue in regions. It lays out potential opportunities for the new entrants, emerging players, and major players in the region. The regional analysis is done after considering the socio-economic factors and government regulations of the countries in the regions.
How you may use our products:
- Correctly Positioning New Products
- Market Entry Strategies
- Business Expansion Strategies
- Consumer Insights
- Understanding Competition Scenario
- Product & Brand Management
- Channel & Customer Management
- Identifying Appropriate Advertising Appeals
8 Reasons to Buy This Report
- Includes a Chapter on the Impact of COVID-19 Pandemic On the Market
- Report Prepared After Conducting Interviews with Industry Experts & Top Designates of the Companies in the Market
- Implemented Robust Methodology to Prepare the Report
- Includes Graphs, Statistics, Flowcharts, and Infographics to Save Time
- Industry Growth Insights Provides 24/5 Assistance Regarding the Doubts in the Report
- Provides Information About the Top-winning Strategies Implemented by Industry Players.
- In-depth Insights On the Market Drivers, Restraints, Opportunities, and Threats
- Customization of the Report Available
Frequently Asked Questions?
Anti-CD20 monoclonal antibodies are a type of antibody that specifically binds to the CD20 antigen on the surface of cancer cells. This allows for the immune system to attack and destroy these cells.
Some of the key players operating in the anti-cd20 monoclonal antibodies market are Genmab, Amgen, Celltrion, Roche, Novartis AG, Pfizer, Biogen, Genentech, Immunomedics, Spectrum Pharmaceuticals, Bio-Rad Laboratories, LFB Biotechnologie.
The anti-cd20 monoclonal antibodies market is expected to register a CAGR of 8.5%.
1. Executive Summary
2. Assumptions and Acronyms Used
3. Research Methodology
4. Anti-CD20 Monoclonal Antibodies Market Overview
4.1. Introduction
4.1.1. Market Taxonomy
4.1.2. Market Definition
4.2. Macro-Economic Factors
4.2.1. Industry Outlook
4.3. Anti-CD20 Monoclonal Antibodies Market Dynamics
4.3.1. Market Drivers
4.3.2. Market Restraints
4.3.3. Opportunity
4.3.4. Market Trends
4.4. Anti-CD20 Monoclonal Antibodies Market - Supply Chain
4.5. Global Anti-CD20 Monoclonal Antibodies Market Forecast
4.5.1. Anti-CD20 Monoclonal Antibodies Market Size (US$ Mn) and Y-o-Y Growth
4.5.2. Anti-CD20 Monoclonal Antibodies Market Size (000 Units) and Y-o-Y Growth
4.5.3. Anti-CD20 Monoclonal Antibodies Market Absolute $ Opportunity
5. Global Anti-CD20 Monoclonal Antibodies Market Analysis and Forecast by Type
5.1. Market Trends
5.2. Introduction
5.2.1. Basis Point Share (BPS) Analysis by Type
5.2.2. Y-o-Y Growth Projections by Type
5.3. Anti-CD20 Monoclonal Antibodies Market Size and Volume Forecast by Type
5.3.1. First Generation Anti-CD20 Monoclonal Antibody
5.3.2. Second Generation Anti-CD20 Monoclonal Antibody
5.3.3. Third Generation Anti-CD20 Monoclonal Antibody
5.4. Absolute $ Opportunity Assessment by Type
5.5. Market Attractiveness/Growth Potential Analysis by Type
6. Global Anti-CD20 Monoclonal Antibodies Market Analysis and Forecast by Application
6.1. Market Trends
6.2. Introduction
6.2.1. Basis Point Share (BPS) Analysis by Application
6.2.2. Y-o-Y Growth Projections by Application
6.3. Anti-CD20 Monoclonal Antibodies Market Size and Volume Forecast by Application
6.3.1. Oncology
6.3.2. Neurology
6.3.3. Immunology
6.4. Absolute $ Opportunity Assessment by Application
6.5. Market Attractiveness/Growth Potential Analysis by Application
7. Global Anti-CD20 Monoclonal Antibodies Market Analysis and Forecast by Sales Channel
7.1. Market Trends
7.2. Introduction
7.2.1. Basis Point Share (BPS) Analysis by Sales Channel
7.2.2. Y-o-Y Growth Projections by Sales Channel
7.3. Anti-CD20 Monoclonal Antibodies Market Size and Volume Forecast by Sales Channel
7.3.1. Manufacturer/Distributor/Service Provider
7.3.2. Aftermarket
7.4. Absolute $ Opportunity Assessment by Sales Channel
7.5. Market Attractiveness/Growth Potential Analysis by Sales Channel
8. Global Anti-CD20 Monoclonal Antibodies Market Analysis and Forecast by Region
8.1. Market Trends
8.2. Introduction
8.2.1. Basis Point Share (BPS) Analysis by Region
8.2.2. Y-o-Y Growth Projections by Region
8.3. Anti-CD20 Monoclonal Antibodies Market Size and Volume Forecast by Region
8.3.1. North America
8.3.2. Latin America
8.3.3. Europe
8.3.4. Asia Pacific
8.3.5. Middle East and Africa (MEA)
8.4. Absolute $ Opportunity Assessment by Region
8.5. Market Attractiveness/Growth Potential Analysis by Region
8.6. Global Anti-CD20 Monoclonal Antibodies Demand Share Forecast, 2019-2026
9. North America Anti-CD20 Monoclonal Antibodies Market Analysis and Forecast
9.1. Introduction
9.1.1. Basis Point Share (BPS) Analysis by Country
9.1.2. Y-o-Y Growth Projections by Country
9.2. North America Anti-CD20 Monoclonal Antibodies Market Size and Volume Forecast by Country
9.2.1. U.S.
9.2.2. Canada
9.3. Absolute $ Opportunity Assessment by Country
9.4. North America Anti-CD20 Monoclonal Antibodies Market Size and Volume Forecast by Application
9.4.1. Oncology
9.4.2. Neurology
9.4.3. Immunology
9.5. Basis Point Share (BPS) Analysis by Application
9.6. Y-o-Y Growth Projections by Application
9.7. North America Anti-CD20 Monoclonal Antibodies Market Size and Volume Forecast by Type
9.7.1. First Generation Anti-CD20 Monoclonal Antibody
9.7.2. Second Generation Anti-CD20 Monoclonal Antibody
9.7.3. Third Generation Anti-CD20 Monoclonal Antibody
9.8. Basis Point Share (BPS) Analysis by Type
9.9. Y-o-Y Growth Projections by Type
9.10. Market Attractiveness/Growth Potential Analysis
9.10.1. By Country
9.10.2. By Product Type
9.10.3. By Application
9.10.4. By Sales Channel
9.11. North America Anti-CD20 Monoclonal Antibodies Demand Share Forecast, 2019-2026
10. Latin America Anti-CD20 Monoclonal Antibodies Market Analysis and Forecast
10.1. Introduction
10.1.1. Basis Point Share (BPS) Analysis by Country
10.1.2. Y-o-Y Growth Projections by Country
10.1.3. Latin America Average Pricing Analysis
10.2. Latin America Anti-CD20 Monoclonal Antibodies Market Size and Volume Forecast by Country
10.2.1. Brazil
10.2.2. Mexico
10.2.3. Rest of Latin America
10.3. Absolute $ Opportunity Assessment by Country
10.4. Latin America Anti-CD20 Monoclonal Antibodies Market Size and Volume Forecast by Application
10.4.1. Oncology
10.4.2. Neurology
10.4.3. Immunology
10.5. Basis Point Share (BPS) Analysis by Application
10.6. Y-o-Y Growth Projections by Application
10.7. Latin America Anti-CD20 Monoclonal Antibodies Market Size and Volume Forecast by Type
10.7.1. First Generation Anti-CD20 Monoclonal Antibody
10.7.2. Second Generation Anti-CD20 Monoclonal Antibody
10.7.3. Third Generation Anti-CD20 Monoclonal Antibody
10.8. Basis Point Share (BPS) Analysis by Type
10.9. Y-o-Y Growth Projections by Type
10.10. Market Attractiveness/Growth Potential Analysis
10.10.1. By Country
10.10.2. By Product Type
10.10.3. By Application
10.10.4. By Sales Channel
10.11. Latin America Anti-CD20 Monoclonal Antibodies Demand Share Forecast, 2019-2026
11. Europe Anti-CD20 Monoclonal Antibodies Market Analysis and Forecast
11.1. Introduction
11.1.1. Basis Point Share (BPS) Analysis by Country
11.1.2. Y-o-Y Growth Projections by Country
11.1.3. Europe Average Pricing Analysis
11.2. Europe Anti-CD20 Monoclonal Antibodies Market Size and Volume Forecast by Country
11.2.1. Germany
11.2.2. France
11.2.3. Italy
11.2.4. U.K.
11.2.5. Spain
11.2.6. Russia
11.2.7. Rest of Europe
11.3. Absolute $ Opportunity Assessment by Country
11.4. Europe Anti-CD20 Monoclonal Antibodies Market Size and Volume Forecast by Application
11.4.1. Oncology
11.4.2. Neurology
11.4.3. Immunology
11.5. Basis Point Share (BPS) Analysis by Application
11.6. Y-o-Y Growth Projections by Application
11.7. Europe Anti-CD20 Monoclonal Antibodies Market Size and Volume Forecast by Type
11.7.1. First Generation Anti-CD20 Monoclonal Antibody
11.7.2. Seond Generation Anti-CD20 Monoclonal Antibody
11.7.3. Third Generation Anti-CD20 Monoclonal Antibody
11.8. Basis Point Share (BPS) Analysis by Type
11.9. Y-o-Y Growth Projections by Type
11.10. Market Attractiveness/Growth Potential Analysis
11.10.1. By Country
11.10.2. By Product Type
11.10.3. By Application
11.10.4. By Sales Channel
11.11. Europe Anti-CD20 Monoclonal Antibodies Demand Share, 2019-2026
12. Asia Pacific Anti-CD20 Monoclonal Antibodies Market Analysis and Forecast
12.1. Introduction
12.1.1. Basis Point Share (BPS) Analysis by Country
12.1.2. Y-o-Y Growth Projections by Country
12.1.3. Asia Pacific Average Pricing Analysis
12.2. Asia Pacific Anti-CD20 Monoclonal Antibodies Market Size and Volume Forecast by Country
12.2.1. China
12.2.2. Japan
12.2.3. South Korea
12.2.4. India
12.2.5. Australia
12.2.6. Rest of Asia Pacific (APAC)
12.3. Absolute $ Opportunity Assessment by Country
12.4. Asia Pacific Anti-CD20 Monoclonal Antibodies Market Size and Volume Forecast by Application
12.4.1. Oncology
12.4.2. Neurology
12.4.3. Immunology
12.5. Basis Point Share (BPS) Analysis by Application
12.6. Y-o-Y Growth Projections by Application
12.7. Asia Pacific Anti-CD20 Monoclonal Antibodies Market Size and Volume Forecast by Type
12.7.1. First Generation Anti-CD20 Monoclonal Antibody
12.7.2. Second Generation Anti-CD20 Monoclonal Antibody
12.7.3. Third Generation Anti-CD20 Monoclonal Antibody
12.8. Basis Point Share (BPS) Analysis by Type
12.9. Y-o-Y Growth Projections by Type
12.10. Market Attractiveness/Growth Potential Analysis
12.10.1. By Country
12.10.2. By Product Type
12.10.3. By Application
12.10.4. By Sales Channel
12.11. Asia Pacific Anti-CD20 Monoclonal Antibodies Demand Share, 2019-2026
13. Middle East & Africa Anti-CD20 Monoclonal Antibodies Market Analysis and Forecast
13.1. Introduction
13.1.1. Basis Point Share (BPS) Analysis by Country
13.1.2. Y-o-Y Growth Projections by Country
13.1.3. Asia Pacific Average Pricing Analysis
13.2. Middle East & Africa Anti-CD20 Monoclonal Antibodies Market Size and Volume Forecast by Country
13.2.1. Saudi Arabia
13.2.2. South Africa
13.2.3. UAE
13.2.4. Rest of Middle East & Africa (MEA)
13.3. Absolute $ Opportunity Assessment by Country
13.4. Middle East & Africa Anti-CD20 Monoclonal Antibodies Market Size and Volume Forecast by Application
13.4.1. Oncology
13.4.2. Neurology
13.4.3. Immunology
13.5. Basis Point Share (BPS) Analysis by Application
13.6. Y-o-Y Growth Projections by Application
13.7. Middle East & Africa Anti-CD20 Monoclonal Antibodies Market Size and Volume Forecast by Type
13.7.1. First Generation Anti-CD20 Monoclonal Antibody
13.7.2. Second Generation Anti-CD20 Monoclonal Antibody
13.7.3. Third Generation Anti-CD20 Monoclonal Antibody
13.8. Basis Point Share (BPS) Analysis by Type
13.9. Y-o-Y Growth Projections by Type
13.10. Market Attractiveness/Growth Potential Analysis
13.10.1. By Country
13.10.2. By Product Type
13.10.3. By Application
13.10.4. By Sales Channel
13.11. Middle East & Africa Anti-CD20 Monoclonal Antibodies Demand Share, 2019-2026
14. Competition Landscape
14.1. Global Anti-CD20 Monoclonal Antibodies Market: Market Share Analysis
14.2. Anti-CD20 Monoclonal Antibodies Distributors and Customers
14.3. Anti-CD20 Monoclonal Antibodies Market: Competitive Dashboard
14.4. Company Profiles (Details Overview, Financials, Developments, Strategy)
14.4.1. Genmab
14.4.1.1. Overview
14.4.1.2. Financials
14.4.1.3. Developments
14.4.1.4. Strategic Outlook
14.4.2. Amgen
14.4.2.1. Overview
14.4.2.2. Financials
14.4.2.3. Developments
14.4.2.4. Strategic Outlook
14.4.3. Celltrion
14.4.3.1. Overview
14.4.3.2. Financials
14.4.3.3. Developments
14.4.3.4. Strategic Outlook
14.4.4. Roche
14.4.4.1. Overview
14.4.4.2. Financials
14.4.4.3. Developments
14.4.4.4. Strategic Outlook
14.4.5. Novartis AG
14.4.5.1. Overview
14.4.5.2. Financials
14.4.5.3. Developments
14.4.5.4. Strategic Outlook
14.4.6. Pfizer
14.4.6.1. Overview
14.4.6.2. Financials
14.4.6.3. Developments
14.4.6.4. Strategic Outlook
14.4.7. Biogen
14.4.7.1. Overview
14.4.7.2. Financials
14.4.7.3. Developments
14.4.7.4. Strategic Outlook
14.4.8. Genentech
14.4.8.1. Overview
14.4.8.2. Financials
14.4.8.3. Developments
14.4.8.4. Strategic Outlook
14.4.9. Immunomedics
14.4.9.1. Overview
14.4.9.2. Financials
14.4.9.3. Developments
14.4.9.4. Strategic Outlook
14.4.10. Spectrum Pharmaceuticals
14.4.10.1. Overview
14.4.10.2. Financials
14.4.10.3. Developments
14.4.10.4. Strategic Outlook
14.4.11. Bio-Rad Laboratories
14.4.11.1. Overview
14.4.11.2. Financials
14.4.11.3. Developments
14.4.11.4. Strategic Outlook
14.4.12. LFB Biotechnologie
14.4.12.1. Overview
14.4.12.2. Financials
14.4.12.3. Developments
14.4.12.4. Strategic Outlook
14.4.13. COMPANY 13
14.4.13.1. Overview
14.4.13.2. Financials
14.4.13.3. Developments
14.4.13.4. Strategic Outlook
14.4.14. COMPANY 14
14.4.14.1. Overview
14.4.14.2. Financials
14.4.14.3. Developments
14.4.14.4. Strategic Outlook
14.4.15. COMPANY 15
14.4.15.1. Overview
14.4.15.2. Financials
14.4.15.3. Developments
14.4.15.4. Strategic Outlook
14.4.16. COMPANY 16
14.4.16.1. Overview
14.4.16.2. Financials
14.4.16.3. Developments
14.4.16.4. Strategic Outlook
14.4.17. COMPANY 17
14.4.17.1. Overview
14.4.17.2. Financials
14.4.17.3. Developments
14.4.17.4. Strategic Outlook
14.4.18. COMPANY 18
14.4.18.1. Overview
14.4.18.2. Financials
14.4.18.3. Developments
14.4.18.4. Strategic Outlook
14.4.19. COMPANY 19
14.4.19.1. Overview
14.4.19.2. Financials
14.4.19.3. Developments
14.4.19.4. Strategic Outlook
14.4.20. COMPANY 20
14.4.20.1. Overview
14.4.20.2. Financials
14.4.20.3. Developments
14.4.20.4. Strategic Outlook
